Document is current
Any future updates will be listed below
-
Authors
Li, Chia-Wei
Lim, Seung-Oe
Xia, Weiya
Lee, Heng-Huan
Chan, Li-Chuan
Kuo, Chu-Wei
Khoo, Kay-Hooi
Chang, Shih-Shin
Cha, Jong-Ho
Kim, Taewan
Hsu, Jennifer L.
Wu, Yun
Hsu, Jung-Mao
Yamaguchi, Hirohito
Ding, Qingqing
Wang, Yan
Yao, Jun
Lee, Cheng-Chung
Wu, Hsing-Ju
Sahin, Aysegul A.
Allison, James P.
Yu, Dihua
Hortobagyi, Gabriel N. https://orcid.org/0000-0002-4873-4412
Hung, Mien-Chie
- License Information
-
More Information
Article History
Received: 13 January 2016
Accepted: 19 July 2016
First Online: 30 August 2016
Competing interests
: M.-C.H. received sponsored research agreement from STCube Pharmaceuticals Inc. through MD Anderson Cancer Center. C.-W.L., S.-O.L. and M.-C.H. are inventors on patent applications under review: Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof, 2016, No. 62/314,652. Combination treatments directed toward programmed death ligand-1 (PD-LI) positive cancers, 2016, No. 62/316,178. Antibodies specific to glycosylated PD-L1 and methods of use thereof, 2016, No. PCT/US16/24691. The remaining authors declare no competing financial interests.
